2,903 reports of this reaction
2.3% of all RUXOLITINIB reports
#5 most reported adverse reaction
HAEMOGLOBIN DECREASED is the #5 most commonly reported adverse reaction for RUXOLITINIB, manufactured by Incyte Corporation. There are 2,903 FDA adverse event reports linking RUXOLITINIB to HAEMOGLOBIN DECREASED. This represents approximately 2.3% of all 126,373 adverse event reports for this drug.
RUXOLITINIB has an overall safety score of 85 out of 100. Patients taking RUXOLITINIB who experience haemoglobin decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOGLOBIN DECREASED is a less commonly reported adverse event for RUXOLITINIB, but still significant enough to appear in the safety profile.
In addition to haemoglobin decreased, the following adverse reactions have been reported for RUXOLITINIB:
The following drugs have also been linked to haemoglobin decreased in FDA adverse event reports:
HAEMOGLOBIN DECREASED has been reported as an adverse event in 2,903 FDA reports for RUXOLITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOGLOBIN DECREASED accounts for approximately 2.3% of all adverse event reports for RUXOLITINIB, making it a notable side effect.
If you experience haemoglobin decreased while taking RUXOLITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.